ATLASTRex Bio, Inc. IPO (TRXB)
The data feed lists TRex Bio, Inc. for NASDAQ with a start date of Oct 9, 2026, status "Priced", and an offer price of $14.00 per the final prospectus (424B4). First-day change from open to close: +3.7%.
Updated November 4, 2026 · Source: IPO calendar data feed (EODHD) and the company's SEC filings
What the company does
TRex Bio, Inc. is a clinical-stage biopharmaceutical company focused on tissue Treg biology for the discovery and development of immunoregulatory medicines designed to restore immune balance and promote tissue repair to address unmet needs of patients with autoimmune and inflammatory diseases. Its most advanced wholly-owned product candidate, TRB-061, is in Phase 1b clinical development in patients with moderate-to-severe atopic dermatitis, and its second candidate, TRB-071, is in IND-enabling studies. The company was founded in 2018 and is based in the United States.
The offer
- Offer price
- $14.00
- Shares offered
- 8,333,334
- Gross proceeds
- $116,666,676
- Net proceeds to the company
- $103.5M ($119.8M with full option)
- Shares outstanding after the offering
- 27,445,682
- Lead underwriters
- J.P. Morgan, Evercore ISI, Cantor, Stifel, Wedbush PacGrow
Use of proceeds
The company intends to use the net proceeds from this offering, together with its existing cash, cash equivalents, and marketable securities: (i) to advance the clinical development of TRB-061, including to fund Phase 2 trials for patients with AD and AA through topline data, (ii) to advance the clinical development of TRB-071, including initiating and completing a Phase 1 trial in healthy volunteers, and (iii) for working capital and other general corporate purposes.
Financials
| US$ thousands | FY2024 | FY2025 | 6M 2025 | 6M 2026 |
|---|---|---|---|---|
| Revenue | 39,108 | 0 | 0 | 0 |
| Net income (loss) | -3,144 | -34,806 | -17,722 | -29,308 |
| Cash and marketable securities | — | — | — | 90,854 |
| Total assets | — | — | — | 96,612 |
Key risks
No approved products, net losses. TRex Bio is an early-stage biotech company with no products approved for commercial sale and has incurred net losses of $3.1 million and $34.8 million for the years ended December 31, 2024 and 2025, respectively, and $29.3 million for the six months ended June 30, 2026.
Accumulated deficit. As of June 30, 2026, the company had an accumulated deficit of $123.6 million and expects to continue to incur significant losses for the foreseeable future.
Clinical trial failure risk. Any product candidate may fail to demonstrate adequate efficacy or an acceptable safety profile, gain regulatory approval or become commercially viable, despite substantial investment in development or commercialization.
Limited operating history. The company has a limited operating history since its inception in 2018 and has not yet demonstrated its ability to successfully obtain regulatory approvals, manufacture a product on a commercial scale, or conduct sales and marketing activities necessary for successful commercialization.
Timeline
- Sep 18, 2026 · Registration statement filed (S-1)
- Oct 5, 2026 · Amendment (S-1/A)
- Oct 9, 2026 · Final prospectus (price set) (424B4) View filing
- Oct 13, 2026 · Current report (8-K)
Sources on SEC EDGAR
Facts come from the company's SEC filings; calendar data from EODHD. Information only, not investment advice. Profile updated Nov 4, 2026.
Calendar data
| Status in feed | Priced |
|---|---|
| Start date | Oct 9, 2026 |
| Exchange | NASDAQ |
| Shares offered | 8,333,334 |
| First-day change (open to close) | +3.70% |
| First-day open | $13.5 |
| First-day close | $14 |
| Filing date | Oct 9, 2026 |
| Last amended | Oct 9, 2026 |
Follow this IPO in ATLAS PRO
IPO alerts are part of ATLAS PRO. Create your account to follow TRXB and get one email when it starts trading.
Create an accountFrequently asked questions
What does TRex Bio, Inc. do?
TRex Bio, Inc. is a clinical-stage biopharmaceutical company focused on tissue Treg biology for the discovery and development of immunoregulatory medicines designed to restore immune balance and promote tissue repair to address unmet needs of patients with autoimmune and inflammatory diseases. Its most advanced wholly-owned product candidate, TRB-061, is in Phase 1b clinical development in patients with moderate-to-severe atopic dermatitis, and its second candidate, TRB-071, is in IND-enabling studies. The company was founded in 2018 and is based in the United States.
How much is the TRex Bio, Inc. IPO raising?
The final prospectus sets a price of $14.00 per share for 8,333,334 shares, or $116,666,676 before expenses and discounts.
Who are the underwriters of the TRex Bio, Inc. IPO?
J.P. Morgan, Evercore ISI, Cantor, Stifel, Wedbush PacGrow.
When is the TRex Bio, Inc. IPO?
The data feed lists a start date of Oct 9, 2026 with status "Priced".
What is the TRex Bio, Inc. IPO price range?
According to the final prospectus (424B4), the offer price is $14.00 per share.
How is the first-day change measured?
On the first trading day (Oct 9, 2026) the stock moved +3.70% from its open ($13.5) to its close ($14), from daily price data. This is not the change from the IPO offer price.
What does "Priced" mean?
The feed reports the offering as priced. The start date is the first trading day.
Can I get an email when this IPO starts trading?
Yes. ATLAS PRO accounts can follow an IPO inside the platform and get one email when it starts trading. This is information, not investment advice.
Educational information, not investment advice. Disclaimer